Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110 (N002)
This study has been completed.
Study NCT00631878   Information provided by Biosynexus Incorporated
First Received: February 29, 2008   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neonatal Staphylococcal Sepsis
Additional conditions recognized in this trial
Bacteremia
Staphylococcal Infections
More general conditions related to this trial
Bacterial Infections
Gram-Positive Bacterial Infections
Infection
Inflammation
Pathologic Processes
Sepsis
Systemic Inflammatory Response Syndrome
Interventions listed in this trial
Pagibaximab (formerly BSYX-A110)
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Biosynexus Incorporated
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services